tirzepatide and nash Novel Dual Incretin Receptor Agonists in the Spectrum of Metabolic Diseases with a Focus on Tirzepatide: Real Game-Changers or Great Expectations? A Narrative Review SYNERGY-NASH: Tirzepatide, a GIP/GLP-1 RA,

Thanh Hng gii thch, d l nhn hng dc m phm cn non tr x s Ph Tang, Sakura vi s mnh mang n sc p, sc kho v hnh phc cho mi ngi, c mt ti Vit Nam t 2014, Dc m phm Sakura c hng triu ph n Vit s dng v tin tng

In the context of GLP-1 therapy, glycine addresses the single biggest concern that clinicians and patients share: losing muscle along with fat

10.1038/s41574-021-00489-y 113 PhaniendraA.BabuD

Besides its glucose-lowering and anti-obesity effects, tirzepatide has been reported to have potential cardiovascular benefits

Slows down the oxidative stress rate High oxidative stress leads to various inflammatory conditions and diseases like diabetes, autoimmune disease, cardiovascular disease and even cancer